ClinicalTrials.gg
RecruitingNCT06499363NEPHYUpdated Sep 3, 2025

Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness

An observational study in Persistent Pulmonary Hypertension of Newborn, sponsored by Ferrer Internacional S.A.. Recruiting at 4 sites in France. Open to participants aged Up to 44 Weeks. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Ferrer Internacional S.A. · Observational

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
60
Ages
Up to 44 Weeks
Sex
All
01

Study summary

This observational study will seek to describe the uses and safety and efficacy outcomes of treprostinil in clinical practice in patients with persistent pulmonary hypertension (PPHN).

02

Conditions studied

  • Persistent Pulmonary Hypertension of Newborn
03

In context

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

This study's planned enrollment of 60 is below the median of 125 across 12 observational studies indexed under Persistent Fetal Circulation Syndrome.

Browse Persistent Fetal Circulation Syndrome studies →

Lead sponsor

Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 44 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Approximately 60 newborns with PH (of whom at least 40 newborns with persistent pulmonary hypertension of the newborn [PPHN]) are expected to be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newborn infants who received at least one dose of IV or SC treprostinil as per clinical practice within 5 years from the moment of data collection.
  2. Aged up to 44 weeks after conception at treprostinil initiation.
  3. Pulmonary hypertension (PH) or suspicion of PH at the moment of treprostinil initiation.
  4. Parent(s) or legally authorized representative(s) provides non-opposition consent for the patient participation in the study.
  5. Newborn infants affiliated to French social security.

Exclusion criteria

Exclusion Criteria:

  • None.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
60 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Characteristics of neonates receiving treprostinil in the clinical practice.

    Sex (male/female) ; Gestational Age (weeks) ; Birth Weight (g) ; Apgar (1 and 5 min, 0-10) and Time from birth to treprostinil initiation (h)

    Time frame: From baseline to Day 30 after last dose of treprostinil

  2. Treprostinil-specific treatment patterns.

    Prior concomitant treatments, treprostinil route, treprostinil dose(s) (mg/ml) and treprostinil treatment duration (days).

    Time frame: From baseline to Day 30 after last dose of treprostinil

  3. Number of participants with treatment-related adverse events to evaluate safety.

    Time frame: From baseline to Day 30 after last dose of treprostinil

Secondary outcomes

  1. Composite endpoint of absence of complications through Day 14 after the index date.

    Time frame: From baseline to Day 30 after last dose of treprostinil

  2. Description of the clinical outcomes from treprostinil start day (i.e., Day 0) to Day 14 and at Day 30 after last dose of treprostinil.

    Evolution of pre- and post-ductal oxygen saturation (SpO2); oxygen partial pressure (PO2); clinical laboratory parameters and fraction of inspired oxygen (FiO2) at times 0h, 24h, 48h, 72h, Day 7, Day 14, and Day 30 after last dose of treprostinil.

    Time frame: 0h, 24h, 48h, 72h, Day 7, Day 14, and Day 30 after last dose of treprostinil (if applicable).

  3. Description of neurodevelopmental progress over 2 years after treprostinil initiation through a Global Clinical Impression Scale.

    Time frame: From day 30 after treprostinil treatment to Year 2 after last dose of treprostinil

07

Study locations

4 of 4 sites recruiting
  • CHU Lyon (HCL) - Hopital Femme Mère Enfant
    Bron, 69500, France
    Recruiting
    • Marine Butin, Medical Doctor · Contactmarine.butin@chu-lyon.fr · +33 (0)4 27 85 52 84
    • Marine Butin, Medical Doctor · Principal investigator
  • Réanimation néonatale CHU Grenoble Alpes - Hôpital Couple Enfant
    Grenoble, 38043, France
    Recruiting
    • Amélie Desrumaux, Medical Doctor · ContactADesrumaux@chu-grenoble.fr · +33(0)4 76 76 55 03
    • Amélie Desrumaux, Medical Doctor · Principal investigator
  • CHU Lille - Clinique de Néonatalogie
    Lille, 59000, France
    Recruiting
    • Kevin Leduc, Medical Doctor · ContactKevin.LEDUC@chu-lille.fr · +33 03 20 44 58 89
    • Kevin Leduc, Medical Doctor · Principal investigator
  • CHU de Toulouse Hopital des enfants - Réanimation Néonatale
    Toulouse, 31300, France
    Recruiting
    • Sophie Breinig, Medical Doctor · Contactbreinig.s@chu-toulouse.fr · +33 (0)5 34 55 84 77
    • Sophie Breinig, Medical Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
Jul 12, 2024
StartActual
Feb 25, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06499363
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Feb 25, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 3, 2025

Study contacts

Ferrer MedInfo
Contact
medinfo@ferrer.com
609850565

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion